At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
We are driven by a desire to help preserve what neurological diseases can take away – how we move, how we think, our very sense of self. Our commitment goes beyond scientific research and development, as we strive to advance health equity and access, work to increase diversity in clinical trials, and collaborate with providers, patient advocacy groups and others toward better health outcomes.
Landon and his sister both live with spinal muscular atrophy (SMA). Learn about his mother Danyelle’s experiences raising two children impacted by SMA.
Advancing Health Access
We continuously adapt our thinking and pioneer responsive approaches to health access. We strive to ensure broad access to our therapies through both public and private healthcare systems, and both before and after a therapy's potential regulatory approval. We run a wide range of Access Programs, and for therapies such as SPINRAZA, we even have Biogen teams available to make home visits to provide personalized support for patients and their families. Read more about our efforts to promote access to SPINRAZA in our Patients section.
Collaborating to Keep MS Patient Treatment on Track
When Biogen’s MS team learned that TYSABRI infusion sites in the U.S. might be impacted by the COVID-19 pandemic, we sprang into action. Our regulatory team worked closely with the U.S. FDA to temporarily allow Biogen to provide in-home TYSABRI infusions during the public health emergency, while remaining compliant with the TYSABRI Outreach Unified Commitment to Health (TOUCH) Prescribing Program.
Biogen is committed to addressing inequities in accessing care for the disease areas we treat. To better meet the needs of underserved and underrepresented patients globally, including in low- and middle-income countries, we advance health equity goals for our clinical trials and maintain an Expanded Access Program to treat patients in more than 40 countries.
To learn more about our approach to health equity and about how we’re increasing representation in clinical trials and engaging patients and providers, visit our Patients section.
Caring for Patient Health
Biogen takes a holistic approach to patient health, with efforts that extend beyond innovative treatments. We work to assist patients in times of crisis; bring their voices into our decision-making; support their providers and partners; and work to promote flexibility, convenience and choice in healthcare.
Visit our Patients section to learn how we promoted patient well-being during the pandemic, how we advocate for patients and about the support we extend to providers and partners.
Pioneering Digital Health Solutions
Biogen continues to create and sponsor digital health solutions to meet the needs of patients and those who care for them. For example, in 2020, we created an online tool for providers, MyBiogen, which helps streamline the process of starting and continuing patients on a Biogen therapy. Providers can access tools and resources to make the process clearer for patients, track the process and keep the internal team informed of patient therapy.
Learn about our other digital health solutions here.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.